| 纯度 | >95%SDS-PAGE. |
| 种属 | Human |
| 靶点 | GZMB |
| Uniprot No | P10144 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 19-247aa |
| 氨基酸序列 | GEIIGGHEAKPHSRPYMAYLMIWDQKSLKRCGGFLIRDDFVLTAAHCWGS SINVTLGAHNIKEQEPTQQFIPVKRPIPHPAYNPKNFSNDIMLLQLERKA KRTRAVQPLRLPSNKAQVKPGQTCSVAGWGQTAPLGKHSHTLQEVKMTVQ EDRKCESDLRHYYDSTIELCVGDPEIKKTSFKGDSGGPLVCNKVAQGIVS YGRNNGMPPRACTKVSSFVHWIKKTMKRY |
| 预测分子量 | 27 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇关于GZMB(Granzyme B)重组蛋白的参考文献示例(内容为模拟概括，仅供参考)：
1. **《High-yield expression and purification of recombinant human Granzyme B in E. coli》**
- 作者：Zhang Y. et al.
- 摘要：研究通过大肠杆菌表达系统高效表达人源GZMB重组蛋白，优化纯化条件获得高活性产物，并验证其在体外诱导肿瘤细胞凋亡的功能。
2. **《Functional characterization of recombinant Granzyme B in immune-mediated cytotoxicity》**
- 作者：Johnson R.L. et al.
- 摘要：利用哺乳动物细胞表达系统制备GZMB重组蛋白，分析其与穿孔素协同作用下的细胞毒性机制，揭示其在T细胞杀伤靶细胞中的关键作用。
3. **《Role of recombinant Granzyme B in chronic inflammation models》**
- 作者：Lee S. et al.
- 摘要：研究重组GZMB蛋白在类风湿性关节炎小鼠模型中的作用，发现其通过调控促炎因子分泌加重炎症反应，提示潜在治疗靶点价值。
(注：以上文献信息为示例，实际引用请通过PubMed或学术数据库查询。)
Granzyme B (GZMB), a serine protease primarily secreted by cytotoxic T lymphocytes (CTLs) and natural killer (NK) cells, plays a critical role in immune-mediated apoptosis. It is stored in cytotoxic granules and delivered to target cells via perforin-dependent mechanisms, where it cleaves specific substrates like caspases and Bid to trigger programmed cell death. Dysregulation of GZMB is linked to autoimmune diseases, chronic inflammation, and impaired tumor immune surveillance. Recombinant GZMB proteins, produced through heterologous expression systems (e.g., E. coli, mammalian cells), enable mechanistic studies of its biological functions, drug discovery, and therapeutic applications. These proteins are engineered with tags (e.g., His-tag) for purification and often undergo post-translational modifications (e.g., glycosylation in mammalian systems) to ensure native-like activity. Researchers use recombinant GZMB to investigate its role in apoptosis pathways, immune checkpoint modulation, and cancer immunotherapy. It also serves as a biomarker for evaluating CTL/NK cell activity in diseases. Quality control involves assessing enzymatic activity, purity (SDS-PAGE), and structural integrity (mass spectrometry). Challenges include maintaining protease stability and avoiding off-target effects due to its broad substrate specificity.
×
